Belgium Data Desk › Health › Collection of real-world evidence for the medicine Prevymis in the context of an article 112 of the Royal Decree of 01/02/2018 (managed entry agreement) with a pay-for-performance mechanism

Collection of real-world evidence for the medicine Prevymis in the context of an article 112 of the Royal Decree of 01/02/2018 (managed entry agreement) with a pay-for-performance mechanism

Prevymis (letermovir) is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). During the reimbursement process of Prevymis, the reimbursement commission (CRM) has proposed to enter in an article

Publisher: Merck Sharp and Dohme
Licence: ODC-BY
Open licence — reuse allowed, usually with attribution
Topic: Health
Type: Dataset
Last updated (catalogue): 2026-08-11
Formats: PDF, CSV, JSON
Contact: msdbelgium@msd.com

Open in Belgium Data DeskPreview, profile and run SQL in your browser

Official page at the publisher ↗

Download link checked on 2026-10-04: 1 of 1 worked. This page describes catalogue information. It does not state that the data is correct.

Collection of real-world evidence for the medicine Prevymis in the context of an article 112 of the Royal Decree of 01/02/2018 (managed entry agreement) with a pay-for-performance mechanism

More in this topic